Matinas Biopharma Holdings Inc (MTNB)

[RealFooFighters]

Let's repeat until it's clear and mainstream

95% survival rate for HIV patients with cryptococcal meningitis at 10 and 18wks with encochleated amphotericin B beats SoC and challengers by 20+ miles

Cohort 2 tells us cohort 4 should succeed with a high probability. Recall patients were sick for weeks before hospitalization so what's an extra 2 days of loading dose of amphotericin B injection replaced by MAT2203 at hospitalization really going to affect. Nothing much. All signs point to MAT2203 doing the bulk work of fungal sterilization of the brain.

You can bet what BPs wouldn't give to provide an oral formulation that works to deliver commonly undruggable treatments for any disease associated to inflammation. I said for years. Many diseases are related to inflammation. Many. Arbutus investors should consider putting one foot in LNC now. Do your DD on (oral) BCS class IV drugs and tell me who else can do it. Extremely few. Thought so (Antihydrogen)